Shares of Egalet Corp (NASDAQ:EGLT) have earned an average recommendation of “Hold” from the six analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $5.38.

A number of research firms have recently weighed in on EGLT. Stifel Nicolaus lowered Egalet from a “buy” rating to a “hold” rating and set a $1.50 price objective for the company. in a research note on Wednesday, January 3rd. Cantor Fitzgerald set a $7.00 price objective on Egalet and gave the stock a “buy” rating in a research note on Friday, December 15th. Finally, Gabelli lowered Egalet from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th.

A number of institutional investors have recently made changes to their positions in EGLT. NJ State Employees Deferred Compensation Plan bought a new position in Egalet during the third quarter valued at approximately $435,000. Goldman Sachs Group Inc. boosted its stake in Egalet by 515.7% during the second quarter. Goldman Sachs Group Inc. now owns 123,454 shares of the specialty pharmaceutical company’s stock valued at $293,000 after buying an additional 103,402 shares during the last quarter. Virtu KCG Holdings LLC boosted its stake in Egalet by 87.0% during the second quarter. Virtu KCG Holdings LLC now owns 79,877 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 37,155 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in Egalet by 0.9% during the second quarter. HighTower Advisors LLC now owns 268,644 shares of the specialty pharmaceutical company’s stock valued at $636,000 after buying an additional 2,408 shares during the last quarter. 50.32% of the stock is owned by institutional investors.

Egalet (NASDAQ:EGLT) traded up $0.02 during midday trading on Friday, hitting $0.84. The stock had a trading volume of 358,700 shares, compared to its average volume of 933,384. The company has a market capitalization of $37.17, a price-to-earnings ratio of -0.24 and a beta of 0.37. The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73. Egalet has a 1 year low of $0.79 and a 1 year high of $5.60.

ILLEGAL ACTIVITY WARNING: “Analysts Set Egalet Corp (EGLT) Target Price at $5.38” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/13/analysts-set-egalet-corp-eglt-target-price-at-5-38.html.

Egalet Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Analyst Recommendations for Egalet (NASDAQ:EGLT)

Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.